Single-arm trial of the second version of an acceptance & commitment therapy smartphone application for smoking cessation
- PMID: 27870987
- PMCID: PMC5183543
- DOI: 10.1016/j.drugalcdep.2016.10.029
Single-arm trial of the second version of an acceptance & commitment therapy smartphone application for smoking cessation
Abstract
Background: The first randomized trial of a smartphone application (app) for adult smoking cessation (SmartQuit 1.0) revealed key features that predict cessation. These findings guided the revision of this Acceptance & Commitment Therapy (ACT)-based application (SmartQuit 2.0), which was primarily tested to examine participant receptivity, short-term cessation and reduction, and the relationship between program completion, smoking cessation and reduction. Secondarily, outcomes were descriptively compared with the SmartQuit1.0 trial.
Method: Adult participants (78% female, 25% with high school or less education, 30% unemployed) were recruited into the single-arm pilot trial (N=99) of SmartQuit 2.0 with a two-month follow-up (85% retention).
Results: Regarding receptivity, 84% of participants were satisfied with SmartQuit 2.0 (vs. 59% for SmartQuit1.0), 73% would recommend it to a friend (vs. 48% for SmartQuit1.0), 81% found the ACT exercises useful for quitting (vs. 44% for SmartQuit1.0). At the 2-month follow-up, the quit rates were 21% for 7-day point prevalence (vs. 23% for SmartQuit1.0), 11% for 30-day point prevalence (vs. 13% for SmartQuit1.0), and 75% of participants reduced their smoking frequency (vs. 57% for SmartQuit1.0). Among program completers (24% of total sample), the quit rates were 33% for 7-day point prevalence, 28% for 30-day point prevalence, and 88% of participants reduced their smoking frequency.
Conclusions: The revised app had high user receptivity, modest quit rates, and high smoking reduction rates. Program completion may be key to boosting the app's effectiveness.
Keywords: Acceptance; Mindfulness; Nicotine dependence; Smartphone; Smoking cessation; mHealth.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statement
Conflicts of Interests. In July 2016, Jonathan Bricker was a consultant to GlaxoSmithKline, the manufacturer of nicotine replacement therapies. Fred Hutchinson Cancer Research Center holds a patent on the ACT app for smoking cessation, and 2Morrow® holds an exclusive license to distribute the app.
Figures
References
-
- Benowitz NL, Jacob P, III, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J, Hansson A, Lichtenstein E, Henningfield J, Tsoh J, Hurt RD, Velicer W (SRNT Subcommittee on Biochemical Verification) Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149–159. - PubMed
-
- Boccio M, Sanna RS, Adams SR, Goler NC, Brown SD, Neugebauer RS, Ferrara A, Wiley DM, Bellamy DJ, Schmittdiel JA. Telephone-based coaching: a comparison of tobacco cessation programs in an integrated health care system. Am J Health Promot. 2015 doi: 10.4278/ajhp.140821-QUAN-424. Epub ahead of print. - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
